Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Genmark Diagnostics

Start price
Target price
Perf. (%)
€11.70
05.10.20
€15.00
19.10.20
-17.52%
19.10.20

Could be worthwhile Investment >10% per year
buy
Pacific Biosciences of California Inc.

Start price
Target price
Perf. (%)
€10.70
05.10.20
€13.00
19.10.20
14.02%
19.10.20

Could be worthwhile Investment >10% per year
buy
Cutera Inc.

Start price
Target price
Perf. (%)
€15.70
05.10.20
€20.00
19.10.20
3.82%
19.10.20

Could be worthwhile Investment >10% per year
buy
CHF Solutions Inc

Start price
Target price
Perf. (%)
-
05.10.20
€1.00
19.10.20
-
19.10.20

Could be very worthwhile Investment >20% year
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€9.45
23.09.20
-
04.11.21
-47.51%
15.07.21

Probably not worthwhile Investment
buy
Bio-Rad Labs Inc. A

Start price
Target price
Perf. (%)
€440.00
22.09.20
-
04.11.21
47.73%
05.11.21

Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€9.90
22.09.20
-
04.11.21
-49.70%
05.11.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€7.40
21.09.20
-
28.09.20
40.54%
28.09.20

Risky Investment
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€7.40
19.09.20
-
29.09.20
72.97%
29.09.20

High risks for its business
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€7.40
19.09.20
-
23.09.20
34.46%
23.09.20

Could be very worthwhile Investment >20% year
buy
Genmark Diagnostics

Start price
Target price
Perf. (%)
€11.20
16.09.20
€12.00
21.09.20
9.82%
21.09.20

Could be worthwhile Investment >10% per year
buy
Pacific Biosciences of California Inc.

Start price
Target price
Perf. (%)
€6.70
16.09.20
€8.00
21.09.20
5.97%
21.09.20

Could be worthwhile Investment >10% per year
buy
Cutera Inc.

Start price
Target price
Perf. (%)
€16.40
16.09.20
€18.00
21.09.20
0.00%
21.09.20

Could be worthwhile Investment >10% per year
buy
CHF Solutions Inc

Start price
Target price
Perf. (%)
-
16.09.20
€0.000
21.09.20
-
21.09.20

Could be very worthwhile Investment >20% year
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€4.94
06.09.20
-
19.09.20
49.80%
19.09.20

High risks for its business
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€3.10
03.09.20
-
03.09.20
-
03.09.20

High risks for its business
buy
PerkinElmer Inc.

Start price
Target price
Perf. (%)
€104.00
03.09.20
-
04.11.21
9.62%
05.11.20

Growths faster than the competition
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
buy
Stratec SE

Start price
Target price
Perf. (%)
€103.60
29.08.20
€120.00
31.08.20
-3.09%
31.08.20

Risky Investment
Stratec SE

Start price
Target price
Perf. (%)
€105.60
28.08.20
€95.00
04.11.21
5.30%
17.06.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
High valuation
Very low/no dividend yield expected
buy
Cardiff Oncology Inc.

Start price
Target price
Perf. (%)
€6.65
22.08.20
-
03.09.20
-11.28%
03.09.20

High risks for its business
buy
Motus GI Holdings Inc.

Start price
Target price
Perf. (%)
€16.70
22.08.20
-
04.11.21
-2.40%
03.06.21

Could be very worthwhile Investment >20% year
buy
CHF Solutions Inc

Start price
Target price
Perf. (%)
-
20.08.20
€2.00
23.08.20
-
23.08.20

Could be very worthwhile Investment >20% year
Idexx Laboratories Inc.

Start price
Target price
Perf. (%)
€321.10
15.08.20
-
16.10.20
12.64%
16.10.20

EBIT growth >5% per year expected
Very low/no dividend yield expected
buy
Teladoc Health Inc

Start price
Target price
Perf. (%)
€164.88
14.08.20
€210.00
04.11.21
24.94%
22.01.21

Future proof or reliable business model
Top 10 in its market
Innovative
Growths faster than the competition
buy
Medtronic plc

Start price
Target price
Perf. (%)
€85.25
10.08.20
-
04.11.21
22.82%
05.11.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Normal challenges to pay loans and raise capital
ROE higher than 15% per year